Lilly Eli & Co (LLY) Holder Hodges Capital Management Has Trimmed Its Position as Stock Value Rose; Novartis A G (NVS) Holder Walter & Keenan Financial Consulting Company Has Lowered Stake as Valuation Declined

Eli Lilly and Company (NYSE:LLY) Logo

Walter & Keenan Financial Consulting Company decreased its stake in Novartis A G (NVS) by 70.54% based on its latest 2018Q1 regulatory filing with the SEC. Walter & Keenan Financial Consulting Company sold 15,800 shares as the company’s stock declined 11.54% with the market. The institutional investor held 6,600 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $534,000, down from 22,400 at the end of the previous reported quarter. Walter & Keenan Financial Consulting Company who had been investing in Novartis A G for a number of months, seems to be less bullish one the $194.81 billion market cap company. The stock increased 3.73% or $2.725 during the last trading session, reaching $75.725. About 2.41 million shares traded or 42.56% up from the average. Novartis AG (NYSE:NVS) has declined 6.45% since June 29, 2017 and is downtrending. It has underperformed by 19.02% the S&P500. Some Historical NVS News: 27/03/2018 – Novartis: Completion of Sale Expected in Second Quarter of 2018; 19/03/2018 – #3 With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell $NVS $RHHBY $REGN; 03/05/2018 – IGNORE: FDA TISAGENLECLEUCEL APPROVAL ANNOUNCED MAY 1; 16/05/2018 – Novartis top lawyer exits over payment to Trump lawyer; 27/03/2018 – GlaxoSmithKline is buying Novartis out of their consumer health care partnership; 16/05/2018 – Novartis announces changes to the Executive Committee; 25/04/2018 – Novartis, Gilead to Get Extra Medicare Coverage for Costly Drugs; 27/03/2018 – NOVARTIS SAYS SALE OF JV IN A NON-CORE SEGMENT IN BEST LONG-TERM INTERESTS OF NOVARTISSHAREHOLDERS; 11/04/2018 – MYLAN AND BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB; 16/05/2018 – NOVARTIS AG NOVN.S CEO SAYS COMPANY IS NOT GOOD AT SUSTAINABLY MANAGING BROAD DIVERSIFICATION AND INTEGRATING NON-INNOVATIVE MEDICINE ACQUISITIONS, CITING ALCON AND SOME GENERICS INTEGRATIONS

Hodges Capital Management Inc decreased its stake in Lilly Eli & Co (LLY) by 59.98% based on its latest 2018Q1 regulatory filing with the SEC. Hodges Capital Management Inc sold 8,300 shares as the company’s stock rose 3.23% while stock markets declined. The institutional investor held 5,538 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $428,000, down from 13,838 at the end of the previous reported quarter. Hodges Capital Management Inc who had been investing in Lilly Eli & Co for a number of months, seems to be less bullish one the $87.46 billion market cap company. The stock increased 0.23% or $0.2 during the last trading session, reaching $85.69. About 822,216 shares traded. Eli Lilly and Company (NYSE:LLY) has risen 5.65% since June 29, 2017 and is uptrending. It has underperformed by 6.92% the S&P500. Some Historical LLY News: 19/04/2018 – FDA STAFF – LILLY HAS NOT FULLY EVALUATED A SAFE AND EFFECTIVE DOSE OF BARICITINIB FOR TREATMENT OF RHEUMATOID ARTHRITIS AND SO COMPLETE RESPONSE WOULD BE ISSUED; 08/03/2018 – PUMA BIOTECHNOLOGY REQUESTS REVIEW OF NEG OPINION ON NERATINIB; 10/05/2018 – Steward Health Care Announces Exclusive Partnership With Soccer Legend Kristine Lilly; 16/04/2018 – BOEHRINGER, LILLY ACADEMIC PACT WITH UNIVERSITY OF OXFORD; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck; 29/05/2018 – NOVO NORDISK SAYS ORAL SEMAGLUTIDE SHOWS SUPERIOR IMPROVEMENT IN HBA1C VS EMPAGLIFLOZIN IN PIONEER 2 TRIAL; 15/03/2018 – MI House GOP: Rep. Lilly to co-chair bipartisan MI Future Caucus; 10/05/2018 – Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion; 08/05/2018 – ASTRAZENECA AZN EMA OKS LYNPARZA: MAINTENANCE OVARIAN CANCER; 15/05/2018 – Eli Lilly: Galcanezumab Meets Primary Endpoint in Phase 3 Study in Episodic Cluster Headache

Analysts await Novartis AG (NYSE:NVS) to report earnings on July, 17. They expect $1.31 EPS, up 8.26% or $0.10 from last year’s $1.21 per share. NVS’s profit will be $3.37 billion for 14.45 P/E if the $1.31 EPS becomes a reality. After $1.28 actual EPS reported by Novartis AG for the previous quarter, Wall Street now forecasts 2.34% EPS growth.

Among 17 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 3 Sell and 9 Hold. Therefore 29% are positive. Novartis Ag had 38 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was upgraded by Argus Research on Thursday, November 10 to “Buy”. UBS downgraded the shares of NVS in report on Friday, April 1 to “Neutral” rating. On Wednesday, December 6 the stock rating was downgraded by Bank of America to “Sell”. Barclays Capital upgraded the stock to “Hold” rating in Friday, June 23 report. Citigroup downgraded Novartis AG (NYSE:NVS) on Tuesday, March 29 to “Neutral” rating. On Friday, October 13 the stock rating was maintained by Cowen & Co with “Hold”. The rating was downgraded by Cowen & Co on Wednesday, April 5 to “Market Perform”. The stock of Novartis AG (NYSE:NVS) has “Neutral” rating given on Wednesday, January 11 by Credit Suisse. The rating was downgraded by Mainfirst to “Underperform” on Wednesday, October 28. The rating was maintained by Leerink Swann on Thursday, June 22 with “Hold”.

More notable recent Novartis AG (NYSE:NVS) news were published by: Seekingalpha.com which released: “Novartis: Exit Sandoz US Now” on June 06, 2018, also Seekingalpha.com with their article: “Translate Bio prices upsized initial public offering” published on June 27, 2018, Fool.com published: “Is Pfizer’s Lead Growth Driver in Trouble?” on June 26, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” published on June 28, 2018 as well as Streetinsider.com‘s news article titled: “Novartis (NVS) Receives Positive CHMP Opinion for Kymriah for Treating Two Aggressive Blood Cancers” with publication date: June 29, 2018.

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.32, from 1.1 in 2017Q4. It is negative, as 76 investors sold LLY shares while 427 reduced holdings. 82 funds opened positions while 308 raised stakes. 810.94 million shares or 1.95% less from 827.08 million shares in 2017Q4 were reported. Westwood Holdings Group Inc Incorporated accumulated 3,460 shares. Advisory Net Lc, a Georgia-based fund reported 13,761 shares. 1.15M were accumulated by Saturna Cap. Rowland Counsel Adv holds 0% or 44,271 shares in its portfolio. Renaissance Tech Limited Liability Corporation holds 0.32% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 3.76M shares. 956,500 are owned by Comgest Investors Sas. Federated Invsts Pa has 391,524 shares. At Bank reported 3,544 shares. Catawba Capital Management Va invested in 12,643 shares or 0.23% of the stock. Regentatlantic Cap Limited holds 0.02% or 2,954 shares in its portfolio. Clean Yield Gru reported 3,023 shares stake. Jp Marvel Invest Advisors stated it has 57,548 shares. Wetherby Asset Mgmt holds 0.18% or 16,780 shares in its portfolio. Lvm Management Mi holds 43,543 shares. 7,703 are held by Jefferies Grp Ltd Llc.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Streetinsider.com which released: “Eli Lilly & Co. (LLY) Highlights Promise of Once-Weekly Trulicity (dulaglutide) in Data from Phase 2 study” on June 25, 2018, also Streetinsider.com with their article: “Eli Lilly & Co. (LLY) Reports Positive Top-Line Results for Second Phase 3 Study of Taltz (ixekizumab) in Ankylosing …” published on June 28, 2018, Streetinsider.com published: “Eli Lilly & Co. (LLY) Highlights New Data from Three Phase 1b Studies Evaluating URLi Compared to Humalog” on June 25, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Streetinsider.com and their article: “Boehringer Ingelheim, Lilly (LLY) Announce Phase III for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes Met …” published on June 25, 2018 as well as Streetinsider.com‘s news article titled: “Lilly (LLY) Initiates Observational Survey of Epidemiology, Treatment and Care of Migraine” with publication date: June 29, 2018.

Since February 1, 2018, it had 1 insider buy, and 19 selling transactions for $92.69 million activity. Another trade for 180,000 shares valued at $15.09 million was sold by LILLY ENDOWMENT INC. Shaw Christi sold 8,426 shares worth $691,775. Conterno Enrique A had sold 25,000 shares worth $2.13 million. $72,981 worth of Eli Lilly and Company (NYSE:LLY) was sold by Zakrowski Donald A on Monday, February 5. On Thursday, June 14 Skovronsky Daniel bought $862,200 worth of Eli Lilly and Company (NYSE:LLY) or 10,000 shares. 9,625 shares were sold by Simmons Jeffrey N, worth $780,780 on Thursday, February 1.

Among 24 analysts covering Eli Lilly and Company (NYSE:LLY), 14 have Buy rating, 1 Sell and 9 Hold. Therefore 58% are positive. Eli Lilly and Company had 107 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was downgraded by DZ Bank to “Hold” on Friday, June 22. The company was maintained on Thursday, August 31 by Piper Jaffray. The firm earned “Sell” rating on Monday, June 5 by BMO Capital Markets. On Monday, May 2 the stock rating was maintained by Leerink Swann with “Outperform”. Credit Suisse upgraded Eli Lilly and Company (NYSE:LLY) rating on Friday, October 9. Credit Suisse has “Outperform” rating and $105 target. Leerink Swann maintained it with “Hold” rating and $98.0 target in Thursday, February 1 report. The stock has “Overweight” rating by Barclays Capital on Friday, October 13. The stock of Eli Lilly and Company (NYSE:LLY) earned “Hold” rating by Leerink Swann on Thursday, August 31. The firm earned “Overweight” rating on Tuesday, December 1 by Barclays Capital. As per Tuesday, May 22, the company rating was maintained by Barclays Capital.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on July, 24. They expect $1.34 EPS, up 20.72% or $0.23 from last year’s $1.11 per share. LLY’s profit will be $1.37 billion for 15.99 P/E if the $1.34 EPS becomes a reality. After $1.34 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Hodges Capital Management Inc, which manages about $2.29B and $1.27 billion US Long portfolio, upped its stake in Propetro Holding Corp by 219,240 shares to 649,740 shares, valued at $10.32 million in 2018Q1, according to the filing. It also increased its holding in Cleveland Cliffs Inc by 1.47M shares in the quarter, for a total of 1.64M shares, and has risen its stake in Facebook Inc Cl A (NASDAQ:FB).

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart